中国已成为全球创新药领域大型授权交易来源国,很多头部跨国制药企业(MNC)已与中国创新药企建立合作关系。根据数据统计,2025年,中国创新药对外合作授权(BD)交易总额累计突破1300亿美元,同比激增超150%。其中,苏州启光德健与美国Biohaven及韩国AimedBio签署的合作协议,总金额高达130亿美元。根据协议,启光德健授予对方ADC药物GQ1011的全球开发与商业化独家授权,以及创新...
Source Link中国已成为全球创新药领域大型授权交易来源国,很多头部跨国制药企业(MNC)已与中国创新药企建立合作关系。根据数据统计,2025年,中国创新药对外合作授权(BD)交易总额累计突破1300亿美元,同比激增超150%。其中,苏州启光德健与美国Biohaven及韩国AimedBio签署的合作协议,总金额高达130亿美元。根据协议,启光德健授予对方ADC药物GQ1011的全球开发与商业化独家授权,以及创新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.